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New technologies in prostate cancer are attempting to change the current prostate cancer pathway by aiming to reduce harms while
maintaining the beneﬁts associated with screening, diagnosis, and treatment. In this article, we discuss the optimal evaluation that new
technologies should undergo to provide level 1 evidence typically required to change the practice. With this in mind, we focus on feasible
and pragmatic trials that could be delivered in a timely fashion by many centers while retaining primary outcomes that focus on clinically
meaningful outcomes. r 2014 Elsevier Inc. All rights reserved.
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The prostate cancer pathway from screening and diag-
nosis to treatment has recently been critically questioned in
light of level 1 evidence pointing to pathway-related harms
that may outweigh the beneﬁts in many men. As a
consequence, recent guidelines have recommended limiting
the systematic use of prostate cancer screening based on
prostate-speciﬁc antigen (PSA) testing to avoid overdiag-
nosis and overtreatment [1–4]. There is a clear requirement
to improve the current therapeutic ratio of the entire
diagnostic and therapeutic pathway with novel interven-
tions. As a result, interest has focused on applying multi-
parametric MRI (mpMRI) in men at risk before biopsy,
targeted biopsy based on mpMRI-derived suspicious
lesions, and tissue-preserving focal therapy.
Although several academic expert centers currently using
these new technologies are attempting to drive the paradigm
changes in the prostate cancer pathway, many others remain
skeptical. The level and degree of evidence required to tipmatter r 2014 Elsevier Inc. All rights reserved.
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o.valerio.12@ucl.ac.uk (M. Valerio).the adoption curves of these new interventions and tech-
nologies to wider dissemination and diffusion is open to
debate. Of particular note, many cite the need for high-
quality studies, which reduce the risk of internal bias, and
maintain that only randomized controlled studies (RCTs)
and systematic reviews of RCTs can change practice across
the board [5–7].
Although it is certainly true that there is an acute lack of
level 1 evidence in the ﬁeld of new interventions for
localized prostate cancer, it is well known that performing
RCTs in surgical sciences is more challenging than in other
medical sciences [8]. In the absence of level 1 evidence in
surgical sciences, there have been examples of widespread
adoption based on high-quality prospective series. For
instance, partial nephrectomy in the treatment of small
renal masses and minimally invasive treatment for penile
cancer are prime examples [9,10].
The key to using prospective single-arm data is to ensure
that such data are of a high quality. In addition to the levels
of evidence deﬁned by Sackett, a mechanism to assess the
quality of evidence in health technology assessment may be
more adequate in surgical sciences [7]. The Grading for
Recommendation Assessment Development and Evaluation
system considers study quality and estimates the degree to
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objective, in addition to the study design, the Grading for
Recommendation Assessment Development and Evaluation
system calculates the quality of evidence considering other
important criteria, which can signiﬁcantly increase or
decrease the overall score. These criteria are risk of bias,
inconsistency, indirectness, imprecision, and publication
bias. Practically, this system considers the external validity
and generalizability of the results of a study as important as
its internal validity.
In this article, we discuss the optimal evaluations that
new technologies in prostate cancer should face to change
the current paradigm, and which the wider urological
community might accept. In doing so, we focus on feasible
(in terms of deliverability) study designs with pragmatic
clinically meaningful outcomes that may be based on
international recommendations and patient/physician con-
sensus. The articles in this guest edition have focused on a
number of elements of pathway change that have been of
particular interest in the last 5 years—namely, target
detection and target ablation. We address each of these
separately.Target Detection
Multiparametric MRI as the ﬁrst test in the pathway
Many prostate cancers currently detected are clinically
insigniﬁcant, meaning that they do not have any clinical
effect on the individual during lifetime [12]. Currently,
the diagnostic pathway for prostate cancer remains heav-
ily reliant on what many accept is a random biopsy
process taken under transrectal ultrasound (TRUS) guid-
ance, which has shown several problems owing to its
nontargeted nature and susceptibility to systematic sam-
pling errors. In addition, TRUS biopsy is a relatively
invasive test that carries the risk of harm to the patient,
such as bleeding, discomfort, and sepsis [13]. These risks
can increase when TRUS biopsies are repeated, which is
often done owing to the poor negative predictive value of
TRUS [14].
A test that is able to triage men to identify those with
likely clinically signiﬁcant prostate cancer might have
considerable clinical utility [15]. Such a test would be
applied when there is an indication for biopsy—usually
because the test showed an elevated PSA level—and prior
to the biopsy itself. Although many biomarkers are being
assessed, imaging in the form of mpMRI may hold the
greatest value in this regard [16]. At present, mpMRI seems
to demonstrate very promising performance characteristics
as a triage tool to exclude clinically signiﬁcant prostate
cancer and select patients who are likely to beneﬁt from
diagnosis [17]. Indeed, in prospective expert center series
with expert reporters, when preoperative mpMRI showed
no suspicious lesion, in 95% of those areas, there was noevidence of disease that many would agree constituted
clinically signiﬁcant cancer on whole-mount step-sectioned
histology using radical prostatectomy specimens [18]. At
the same time, mpMRI is a noninvasive test, which does not
carry the same concerns related to TRUS biopsy complica-
tions. Despite these results, mpMRI is still used by only a
few experienced centers because the level of evidence
cannot be considered of high enough quality to change
practice.
Why is there doubt about the literature? Arguably, the
current literature is limited by a number of biases. The
studies published have mostly evaluated mpMRI after
biopsy, which compromises results owing to biopsy artifact,
and so the accuracy of mpMRI might have been under-
estimated. In addition, many groups have limited the
correlation of mpMRI with histology to the peripheral zone
alone. Furthermore, the reference test is a signiﬁcant source
of bias in itself. Most studies have used radical prostatec-
tomy as comparator, leading to selection of only patients
who have cancer and who then choose or are recommended
to have surgery. Men with borderline or abnormal PSA,
those who had negative result on TRUS biopsy—which
might actually be positive or negative if they were to
undergo an accurate veriﬁcation test—or those who opted
for other treatments would not be assessed. Furthermore, for
diagnostic tests to be deemed reliable, they must be
assessed for test-retest reliability and show consistent results
in terms of interobserver and interitem variation. Finally, to
be deemed valid, diagnostic tests should have face validity
and content validity. Face validity is the degree to which
the results of a test actually represent the measured values,
whereas content validity attempts to verify that the method
of measurement (here mpMRI) actually measures what
it is expected to measure (benign and malignant prostate
tissue).
The Standards for Reporting of Diagnostic Studies
(STARD) statement has provided researchers with mini-
mum requirements for reporting studies that evaluate
diagnostic tests. The checklist in essence allows researchers
to design high-quality study designs [19]. Thus, level 1
evidence for diagnostic tests includes the paired validating
cohort design as it overcomes the biases mentioned before
and retains both internal and external validity [15]. The
paired validating cohort study design includes the index test
(under evaluation), the reference test for accuracy valida-
tion, and the standard test(s) applied to all participants in the
study. All tests are conducted in a blinded fashion by a
priori deﬁned standard operating procedures.
The Prostate MRI Imaging Study (PROMIS) was
designed to avoid common pitfalls in diagnostic trial design
that lead to inaccurate estimation of test accuracy [20,21].
PROMIS is a multicenter validating paired cohort study
where all patients undergo the index test (mpMRI) and then
proceed to have the standard test (TRUS biopsy) and the
reference test (transperineal prostate mapping with 5-mm
sampling density). Template prostate mapping biopsies are
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and this population, as they have excellent accuracy and can
be applied to all men in the study, regardless of the index
test outcomes [22].
This paired validating cohort design has several advan-
tages [15]. The trial recruits all patients who have been
recommended a biopsy, and each patient is evaluated by the
3 tests; thus, spectrum and selection biases are minimized.
In addition, rigorous blinding of each test result is employed
as the ﬁndings of each test are reported centrally and not
released to patients or to other health care professionals
within any of the centers. Therefore, patients and all
clinicians, including radiologists, urologists, and patholo-
gists, will remain blinded to the results until all tests have
been reported and those reports locked. This would
eliminate workup bias or any effect that knowledge of the
imaging may have on the manner in which the biopsies are
conducted. Finally, standard operating procedures detailing
the method of conducting and reporting all 3 tests avoid
variation in the technique from one clinician to another.
These standards are especially helpful in the multicenter
setting of PROMIS. On the contrary, the multicenter setting
also contributes to the strength of this design as it is simply
not enough to evaluate the accuracy of mpMRI alone in 1
specialized center (one of the problems with the current
literature), but it is more important to determine how
feasible it would be to use an mpMRI-based pathway
across a health care system (scanner availability, reporter
training/expertise, and interobserver variation).
Biopsy of the target lesion
Currently, the diagnostic pathway for prostate cancer is
not inﬂuenced by the location of prostate cancer foci in a
particular patient but rather deploys the needles to areas of
the prostate likely to harbor disease (predominantly the
peripheral zone). As a result, some areas are systematically
undersampled such as the base and apex as well as large
areas of the peripheral zone itself [23].
A systematic review comparing the accuracy of an MRI-
derived targeted biopsy with standard TRUS biopsy for the
detection of clinically signiﬁcant disease has recently shown
that the use of a targeted approach decreases the number of
biopsies and at the same time improves cancer risk
stratiﬁcation [24]. As a result, this new strategy may
improve the selection of patients for active management,
may decrease the number of biopsy-related adverse events
by decreasing the number of samples taken, and may confer
a more accurate diagnosis. However, this systematic review
stated that most of the studies included were noncompliant
with the standards described in the STARD statement and
the evidence could not be considered of a high quality [19].
Clearly, a standardized approach to conducting and report-
ing these studies is needed.
Attempting to improve the quality of evidence, a recent
statement has guided researchers with recommendations onhow to report the results of series comparing standard
biopsy to targeted biopsy, and in effect guide the conduct of
such studies in a prospective manner. The Standards of
Reporting for MRI-targeted Biopsy Studies of the prostate
recommendations have provided a list of preferred termi-
nology to use, a detailed checklist of items, and the trial
design information that should be detailed when reporting
such studies [25]. It also emphasized the need to report the
conduct of the diagnostic mpMRI speciﬁcally regarding the
scanner details and the sequences used. The biopsy proce-
dure itself should also be reported explaining the method
used to obtain the samples, whether the operator was
blinded to the diagnostic images, and whether standard or
targeted biopsies had been taken ﬁrst. Furthermore,
researchers were also advised to separately report in a
3  3 table the results of standard versus targeted biopsy
regarding presence of clinically signiﬁcant disease, of
clinically insigniﬁcant disease, and any cancer. These
recommendations should improve study quality and facili-
tate the progressive building of robust evidence by allowing
investigators to collate and meta-analyze data from a
number of groups.
It is also important to emphasize that to provide level 1
evidence of superiority of a new diagnostic modality, the
methodology should be rigorous as per the STARD state-
ment [19]—poor studies simply reporting to the points of
the Standards of Reporting for MRI-targeted Biopsy Studies
do not ensure that the study is of good quality [15].Target ablation
Tissue-preserving focal therapy
The UK Medical Research Council recently updated its
guidelines for evaluating complex interventions, such as
surgical procedures [26]. These recommendations include
the consideration of alternative designs to RCTs, the use of
pilot studies to guide the design of effectiveness trials, the
use of experimental designs when possible to boost recruit-
ment and study completion, and ﬁnally the use of several
clinically meaningful outcomes, with possible subgroup
analysis if necessary with larger samples. This may all
sound intuitive and logical, but this document was a
response to the acknowledgment that the evaluation of
complex/surgical interventions is more challenging than the
evaluation of drugs for several reasons. First, the effective-
ness of one intervention is highly dependent on the skills
not only of the surgeon but mainly of a team composed of
many health care professionals, each playing an essential
interconnected role. Thus, the generalizability of the results
of 1 surgical team might be very limited. Second, tradi-
tional RCTs comparing a new intervention to a standard
one are very difﬁcult to deliver both because surgeons may
not be equally skilled in the 2 interventions evaluated and
because the patient and surgeon may have a more strong
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physician equipoise). Finally, the use of placebo and the
employment of effective blinding are rarely feasible or
ethical in surgery.
In an attempt to both highlight these differences and
advise researchers, funding agencies, and regulatory bodies
on how to evaluate surgical innovations in a robust manner,
the Balliol Collaboration has recently released recommen-
dations, which are reported in the Innovation, Development,
Exploration, Assessment, and Long-term study (IDEAL)
guidelines [27–30]. Essentially, the assessment of surgical
innovation develops in stages, as drugs are developed in
phases, but in practice, the development may not be linear,
stages may sometimes overlap, and not all stages are always
required to develop a procedure.
Recently, the Food and Drug Administration launched a
consultation on trial design in the localized prostate cancer
space, speciﬁcally with respect to trial design that might
lead to approval of novel therapeutics in localized prostate
cancer treatment [31]. The panel included urologists,
medical oncologists, radiation oncologists, patient repre-
sentation, Food and Drug Administration committee mem-
bers, and industry. The ofﬁcial transcript of the workshop
has not been released yet, but during the discussion, it was
acknowledged that the assessment of focal therapy in
prostate cancer using a given source of energy against
standard treatment is more complicated than the assess-
ment of other new technologies in other ﬁelds. Indeed, as
standard treatments include radical whole-gland treat-
ments, using surgery or radiotherapy, the process of
evaluation needs not only take into account the new
technology but also the novel approach. Although no
deﬁnitive conclusion on the ideal design of 1 trial aiming
to lead to approval of novel devices was achieved, several
issues were raised in terms of speciﬁc aspects that should
be considered by researchers when structuring these
interventional trials.
Nonetheless, we now consider the speciﬁc aspects of
patient population, intervention, comparator, outcomes, and
trial design that are debated in the ﬁeld.
Patient population
According to level 1 evidence arising from the PIVOT
trial, patients at low risk do not beneﬁt from active
treatment, at least after a median follow-up of 10 years
[32]. As a result, many have strongly advised that this
population should not be targeted by new technologies.
Certainly, although at present most of these men are being
treated rather than managed on a program of active
surveillance, such an argument may not be a clear justiﬁ-
cation for focal therapy in this population or for that matter,
approving new technologies that use this group within
regulatory trials. Equally, it might be questionable to target
patients at very high risk, as there is deﬁnitive evidence that
these patients do beneﬁt from radical treatment and may
even require multimodal therapy [32]. Therefore, patients atintermediate and those with low-volume/burden organ-
conﬁned high-risk disease seem to be the ideal target
population for a novel intervention that attempts to reduce
the harms of current treatments but retain the clear beneﬁts
that radical treatments confer on prostate cancer mortality
[32]. This is a signiﬁcant shift as focal therapy has been
usually considered an alternative to active surveillance,
which essentially includes patients at low risk who today
are arguably safely managed by active surveillance in the
medium and long term [5].
Deﬁning the intervention
There is no agreement as to the boundaries and extent of
tissue ablation that constitutes focal therapy [33]. Many
researchers assert that every approach that is able to
spare tissue to whatever extent should be considered a
“focal approach” [34]. Others argue that true focal therapy
is the ablation of an imaging-derived or biopsy-derived
target with a certain margin (yet to be deﬁned) and that the
indiscriminate ablation of part of the prostate including
noncancerous tissue should rather be called “subtotal
ablation” [33,35]. Although this debate remains open and
of rather limited interest to most physicians, researchers
evaluating a focal approach should clearly apply and report
the ablation strategy along with the treatment-speciﬁc
parameters to make their ﬁndings as clear as possible.
Comparator
If men at intermediate and high risk represent the target
population, the comparator of the index intervention should
be the current standard, which are radical treatments, either
whole-gland radiation therapy or prostatectomy. Although
it is still unclear which of these 2 treatments has the best
oncological or functional outcome because no high-quality
comparative study has been successfully completed, the
toxicity proﬁle is different, with surgery having more
genitourinary issues in contrast with radiation therapy
having more bowel consequences; however, both show
remarkably similar rates of all these toxicities [36,37].
Furthermore, the time point at which the toxicity after
treatment appears is different with surgery and radiation
therapy, immediate versus delayed, respectively [36]. Both
treatments could be chosen in a very pragmatic manner so
that focal therapy is compared with “radical therapy” as
a class intervention, but it may be important to choose
only one of these interventions to diminish the confounders
and to have consistent outcomes across the 2 arms of an
RCT, especially if mortality is not chosen as the primary
outcome.
Outcomes
Cancer-related treatments are usually compared using
primary measures based on overall or cancer-speciﬁc
survival. However, as the natural history of prostate cancer
is prolonged, a new trial using this outcome would require a
minimum follow-up of approximately 10 to 15 years to
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to 2 different active treatments and might even need to be
powered as an extremely large noninferiority trial [32]. As a
surrogate, in traditional whole-gland treatments, PSA
kinetics have been used with different thresholds according
to each kind of therapy to allow comparisons between
different approaches with the same technique, or among
different techniques. At present, the use of PSA kinetics in
focal therapy is not validated especially as it is difﬁcult to
derive a PSA measure that adjusts for ablated cancer/tissue
and nonablated cancer/tissue [34]. Therefore, pragmatic
outcomes—such as local cancer-control measures and
toxicity-related outcomes—seem the only current feasible
measures to allow comparison between focal therapy and
traditional whole-gland treatments. Local cancer control
should be used as a composite outcome, including the need
for additional local or systemic treatment and the presence
of clinically signiﬁcant residual disease as determined by
histological veriﬁcation using tests with accurate negative
predictive value or by mpMRI if this test would be
validated in monitoring after focal therapy. Furthermore,
toxicity-related outcomes and quality-of-life measures can
allow a standardized and reliable measure of the effect
difference of 1 treatment over another. This pragmatic
outcome seems extremely important in treatments for
prostate cancer given the actual imbalance between harms
and beneﬁt. Finally, different approaches and techniques
should be challenged by a cost-utility perspective. In fact, as
current procedures are increasingly challenged from an
economic point of view, in the very near future, the efﬁcacy
point of 1 treatment over another is likely to be propor-
tioned with its cost. In the UK, this is required by both trial
funders and health care funders.
Trial design
Various designs can be used to evaluate a new device or
intervention.
Cohort single-arm studies
High-quality large multicenter single-arm prospective
development trials may probably lead to regulatory appro-
val of a new technology, which does not necessarily
translate into wider dissemination [38]. Indeed, this kind
of trial is recommended by the IDEAL guidelines when
researchers are assessing a new technology in stage 2b as it
allows testing the effectiveness of a technology in an early
phase [27]. Furthermore, this kind of trial has some
advantages as compared with comparative trials as it is less
demanding in terms of cost, it allows the participation of
many centers, and it allows an enhanced recruitment owing
to the absence of randomization. Nevertheless, to permit the
adoption of a new technology as standard of care, com-
parative trials might still be necessary following this stage,
depending on the degree of patient and physician equipoise
remaining.Comparative effectiveness research
To assess the superior effectiveness of a new technology
against the standard of care, and therefore change the
current practice, the IDEAL guidelines suggest the use of
traditional explanatory RCTs, pragmatic RCTs, or alter-
native designs [27]. The US National Institute of Health
deﬁnition of comparative effectiveness research is “com-
parative effectiveness research is the conduct and synthesis
of research comparing the beneﬁts and harms of different
interventions and strategies to prevent, diagnose, treat and
monitor health conditions in “real world” settings” [39].
In localized prostate cancer, RCTs have been difﬁcult to
recruit to with various trials closing prematurely owing to lack
of recruitment arising from lack of physician or patient
equipoise, or both [40–42]. Yet, rather ironically, most
physicians and patients would agree that novel interventions
in this disease state are very much needed. Therefore, if
traditional explanatory RCTs are difﬁcult to carry out,
pragmatic designs should be used to provide evidence of
effectiveness or ineffectiveness of focal therapy. From a
methodological point of view, trials are generally distin-
guished in explanatory and pragmatic manner. Explanatory
trials address the question whether a given procedure can
work under ideal conditions in a very selected study
population, whereas pragmatic trials answer the question
whether a given procedure does actually work in the “real
world” using a population with broad entry criteria [43]. In
other words, explanatory trials have high internal validity but
may have limited external validity, whereas pragmatic trials
may incorporate more systematic errors but usually allow
wide generalization. As pragmatic trials have easier study
design, they are more practicable. For instance, some of the
most challenging features to apply in explanatory trials
evaluating surgical procedures—such as blinding, strict ran-
domization process, and formal randomization in the same
unit—are more ﬂexible in pragmatic trials. Cohort multiple
RCTs, cluster RCTs, randomized trials by referral, and
randomized consent designs, in which consent is asked after
randomization, are all pragmatic trials with speciﬁc character-
istics that can provide high levels of evidence for the
effectiveness of a treatment compared with another [26,44,45].
Alternative comparative nonrandomized trials are also
feasible [26]. The main advantage of these trials is that they
are structured to be feasible in the real world within the actual
health care delivery systems. The effectiveness of 1 inter-
vention against the current standard can be assessed by
comparing the outcomes of parallel cohorts with nonrandom-
ized allocation [27]. In this setting, the selection bias might be
limited by matching patients with similar baseline character-
istics across the 2 cohorts. Furthermore, controlled interrupted-
time series studies are alternative designs that allow evident
comparison of the interventional group with a control group,
but do have certain selection biases [27]. Finally, tracker trials
in which clinicians allocate patients to different arms based on
their own judgment can also allow wide generalizability, but
clearly the results may be affected by systematic errors [46]. In
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more deliverable than the traditional ones, it should be pointed
out that they do retain certain selection biases regardless of the
methodological adjustment employed. Without randomization,
signiﬁcant selection bias might occur that is difﬁcult to
eliminate by matching or statistical adjustment. These include
tumor-related parameters and difference in risk of competing
mortality in men choosing active surveillance, focal therapy,
radical prostatectomy, or external beam radiotherapy. Within
the same risk category, men undergoing radiotherapy may
have higher risk tumors and higher competing risks than
patients undergoing prostatectomy. As a result, large sample
sizes and long follow-up periods are often needed to detect the
relatively small overall survival differences.Conclusions
New technologies might be the answer to counterbalance
the shortcomings of the current prostate cancer pathway,
from diagnosis to treatment. However, high-quality evi-
dence for the superiority of these new technologies in terms
of accuracy, efﬁcacy/effectiveness, and cost-effectiveness is
needed to drive the change in the current paradigm, and to
allow their dissemination, if truly found to have clinically
meaningful positive attributes over the standard pathway.
The alternatives to conducting and facilitating high-quality
studies are equally grave. The ﬁrst error is to reject the
novel alternatives although they may actually improve the
lives of our patients. The second error is to accept the novel
alternatives when in fact they are harmful to our patients.
High-quality trials that are deliverable in a cost-efﬁcient and
timely manner are urgently needed for the beneﬁt of all men
who are concerned about having prostate cancer or are
currently entangled in making treatment choices between
the exhaustive list of therapeutic options available to them.
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